GENO Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 28.05 |
| 52 Week High | SEK 53.90 |
| 52 Week Low | SEK 19.00 |
| Beta | 1.64 |
| 11 Month Change | 23.03% |
| 3 Month Change | 15.91% |
| 1 Year Change | -41.44% |
| 33 Year Change | -61.47% |
| 5 Year Change | -8.33% |
| Change since IPO | -73.79% |
Recent News & Updates
Recent updates
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 19
Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings
Aug 28Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts
Aug 21Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Aug 12Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors
May 31This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 4.9% | -5.8% | -2.8% |
| 1Y | -41.4% | 26.0% | 13.4% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 26% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 13.4% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 12.4% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: GENO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: GENO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market cap | SEK 1.80b |
| Earnings (TTM) | SEK 27.91m |
| Revenue (TTM) | SEK 130.57m |
65.8x
P/E Ratio14.1x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | SEK 130.57m |
| Cost of Revenue | SEK 15.13m |
| Gross Profit | SEK 115.44m |
| Other Expenses | SEK 87.53m |
| Earnings | SEK 27.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 88.41% |
| Net Profit Margin | 21.38% |
| Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparison